Navigation Links
The Journal of Allergy and Clinical Immunology devotes special issue to AIDS
Date:7/31/2008

Philadelphia 31 July 2008 The editors of The Journal of Allergy and Clinical Immunology are pleased to announce the July issue, highlighting AIDS and AIDS research. The Journal of Allergy and Clinical Immunology (http://www.jacionline.org/) is the official journal of the American Academy of Allergy and Clinical Immunology, and is published by Elsevier.

The issue coincides with the XVII International AIDS Conference, taking place at Centro Banamex, Mexico City, August 3 to 8, 2008. Donald M. Leung, Editor-in-Chief said, "AIDS is a topic of global importance and we believe that this collection of articles, written by some of the leading figures in HIV and AIDS research, will be of great interest to the many researchers and clinicians gathering in Mexico City."

Key papers include a review article by Barton F. Haynes from Duke University and Robin J. Shattock from St. George's University of London that summarizes some of the hurdles that researchers face in developing an HIV vaccine. Additionally, a mechanistic review by Susan Moir and Anthony S. Fauci from the National Institutes of Health's National Institute of Allergy and Infectious Diseases looks specifically at B-cell abnormalities associated with HIV, in the hopes that as the authors state in their article "A better understanding of the pathogenic mechanisms of B-cell abnormalities [] can potentially lead to new strategies for improving antibody responses."

Also, a Rostrum article by Lin Shen and Robert F. Siliciano from Johns Hopkins University argues that highly active antiretroviral therapy (HAART) must be combined with new techniques to attack the viral reservoirs that remain even after viral replication has been stopped.

Other issue highlights include original research from a National Institutes of Health multi-center group that finds an increased rate of asthma in HIV-infected children who are being treated with HAART; the report of genetic variations in the innate immune mannose lectin-binding pathway that changes the rate of HIV disease progression; and the laboratory advancement of measuring nave and late activated cytotoxic T lymphocytes as a simpler method of measuring thymic function.

Subscribers can access the full content of each issue of The Journal of Allergy and Clinical Immunology at the journal web site, www.jacionline.org. Institutional subscribers can access the journal through ScienceDirect, http://www.sciencedirect.com/science/journal/00916749.

Visitors to the XVII International AIDS Conference in Mexico City are encouraged to stop by the Elsevier display (Booth #503) to see the special AIDS issue and to learn how to subscribe to The Journal of Allergy and Clinical Immunology subscriber.


'/>"/>

Contact: Caroline Foote
c.foote@elsevier.com
215-239-3653
Elsevier
Source:Eurekalert

Related medicine news :

1. Alzheimers & Dementia: The Journal of the Alzheimers Association accepted for coverage in MEDLINE
2. 5.634 -- the new impact factor of European Urology underlines the journals outstanding position
3. Chicago-Based Speaker/Author Concurs with Research Finding of Using Journaling as a Tool to Combat Obesity and Other Health Problems
4. Human Factors Journal celebrates 50 years
5. Global Access Project (GAP) Study Examining Patients Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA)
6. Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information
7. American Heart Association Announces Fourth New Journal - Circulation: Cardiovascular Interventions to Debut in August
8. Elsevier announces 2007 journal impact factor highlights
9. Journal STEM CELLS Presents 3rd Annual Young Investigator Award at International Stem Cell Symposium
10. Dermatology Nurses Association Teams with International Publisher to Launch its Own Journal
11. Long-term safety data on Lialda published in leading GI journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. ... thick and thin. The beauty of the Lithuanian language and its poetry ... this poetry book, Zubinas lyrically explores all aspects of a living, breathing forest where ...
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... a patent-pending blend of L-Citrulline and glutathione to enhance production of nitric oxide ... that studies have shown to produce NO twice as effectively and sustains NO ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... and geographic lines. The goal of Castlewood Treatment Centers has always been to ... accessible to as many people as possible. In that spirit, Castlewood has announced ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   BIOTRONIK today announced ... The study evaluates the safety and feasibility of performing ... office setting. BioMonitor 2 is an insertable ... is placed underneath a patient,s skin to help physicians ... Atrial fibrillation is a leading cause of stroke and ...
(Date:12/5/2016)... , Dec. 5, 2016  Wellbridge Health and Gateway Health ... health solutions to Medicare and Medicaid plan members with specific ... at the unique needs of this group of consumers, Wellbridge ... work philosophies to provide insight into members, daily behaviors and ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: